ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

類似資料

• inhibitors in non-small cell lung cancer: the latest evidence and developments
  著者:: Ivana Sullivan, 等
  出版事項: (2016-01-01)
• Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience
  著者:: Sullivan, Ivana, 等
  出版事項: (2016)
• Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
  著者:: Liao, Bin-Chi, 等
  出版事項: (2015)
• Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”
  著者:: Sullivan, Ivana, 等
  出版事項: (2016)
• Second- and third-generation ALK inhibitors for non-small cell lung cancer
  著者:: Wu, Jingjing, 等
  出版事項: (2016)